Gaxin Xia
Shanghai biotech tackling kidney disease gets another round of cash
Four months after a secretive Shanghai biotech pulled in $60 million for a Series B round, it’s returning to the fore with a little more …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
